Familial hypercholesterolaemia: trials for referral
134 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
134 trials shown
Phase 41 site
Not yet recruitingPakistan
NCT07909915
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease
Rehman Medical Institute - RMI
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 32 sites
RecruitingIndia
NCT07821944
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)
Merck Sharp & Dohme LLC
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govNo phase2 sites
RecruitingUnited States
NCT06568601
Pharmacogenomic Informed Statin Prescribing
VA Office of Research and Development
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 4149 sites
RecruitingUnited States
NCT06909565
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Duke University
Pre-treatment window Registry sentence: “Any prior treatment with inclisiran”
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 1/22 sites
Not yet recruitingAustralia
NCT07894887
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Editas Medicine, Inc.
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 36 sites
RecruitingDenmark, Netherlands, Norway, Poland, Sweden, United States
NCT07473843
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 118 sites
RecruitingAustralia, Canada, United Kingdom, Netherlands, United States, South Africa
NCT06451770
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Verve Therapeutics, Inc.
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 2/354 sites
RecruitingAustralia, Belgium, Brazil, Chile, China, Colombia
NCT07058077
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Merck Sharp & Dohme LLC
Registry updated 7 Oct 2026
Registry record: ClinicalTrials.govPhase 312 sites
Not yet recruitingGermany, Spain, Italy
NCT07474649
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
Daiichi Sankyo
Pre-treatment window Registry sentence: “Lipid-lowering treatment-naïve”
Registry updated 29 Sept 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT06743659
Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia
Brigham and Women's Hospital
Registry updated 29 Sept 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07839936
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
Verve Therapeutics, Inc.
Registry updated 24 Sept 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
RecruitingPakistan
NCT07832578
Comparison of Aspirin Alone Versus Low-Dose Rivaroxaban Plus Aspirin in Chronic Limb-Threatening Ischemia
King Edward Medical University
Registry updated 22 Sept 2026
Registry record: ClinicalTrials.govPhase 40 sites
Not yet recruiting
NCT07803679
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
Amgen
Registry updated 21 Sept 2026
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingAustralia, New Zealand
NCT07428473
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
Monash University
Registry updated 21 Sept 2026
Registry record: ClinicalTrials.govPhase 347 sites
RecruitingArgentina, Brazil, Canada, Switzerland, Czechia, Germany
NCT05682378
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
Novartis Pharmaceuticals
Registry updated 18 Sept 2026
Registry record: ClinicalTrials.govPhase 117 sites
RecruitingAustralia, United Kingdom, New Zealand, United States
NCT07491172
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
CRISPR Therapeutics AG
Registry updated 18 Sept 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
RecruitingChina
NCT06125847
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
First Affiliated Hospital Xi'an Jiaotong University
Pre-treatment window Registry sentence: “Untreated LDL-C ≥10 mmol/L (386mg/ dL) or treated LDL-C ≥7 mmol/L (270mg/ dL) together with cutaneous or tendon xanthoma before age 18 years;”
Registry updated 3 Sept 2026
Registry record: ClinicalTrials.govPhase 127 sites
RecruitingAustralia, Canada, United Kingdom, Israel, New Zealand, United States
NCT06164730
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
Verve Therapeutics, Inc.
Registry updated 2 Sept 2026
Registry record: ClinicalTrials.govPhase 35 sites
Not yet recruitingIsrael, India, New Zealand, South Africa
NCT07775339
Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial Hypercholesterolemia
LIB Therapeutics LLC
Registry updated 25 Aug 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07777003
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 in Healthy Subjects and Subjects With Mildly Elevated LDL-C Levels
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Registry updated 20 Aug 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT04941599
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
Vanderbilt University Medical Center
Registry updated 7 Aug 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT07591298
Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Registry updated 31 Jul 2026
Registry record: ClinicalTrials.govPhase 227 sites
RecruitingUnited States
NCT07610278
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
Novartis Pharmaceuticals
Registry updated 30 Jul 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT06700408
RCT for the Chinese Medicine in Treating Hypercholesterolemia
Chinese University of Hong Kong
Registry updated 30 Jul 2026
Registry record: ClinicalTrials.govPhase 37 sites
By invitation onlyIsrael, Norway, New Zealand, United States, South Africa
NCT07102511
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
LIB Therapeutics LLC
Registry updated 28 Jul 2026
Registry record: ClinicalTrials.govPhase 319 sites
RecruitingAustria, China, Germany, United Kingdom, Greece, Malaysia
NCT06597006
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals
Registry updated 24 Jul 2026
Registry record: ClinicalTrials.govPhase 410 sites
RecruitingJapan
NCT07634484
A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins
Kowa Company, Ltd.
Registry updated 13 Jul 2026
Registry record: ClinicalTrials.govPhase 31 site
RecruitingChina
NCT07465263
A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Registry updated 8 Jul 2026
Registry record: ClinicalTrials.govPhase 41 site
Not yet recruitingChina
NCT07674368
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
Hunan Cancer Hospital
Registry updated 1 Jul 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingSouth Korea
NCT07524101
Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD
Yonsei University
Registry updated 16 Jun 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States40 open trials
- China20 open trials
- Italy12 open trials
- Spain11 open trials
- Netherlands10 open trials
- United Kingdom10 open trials
- France9 open trials
- Australia7 open trials
- South Africa7 open trials
- Germany7 open trials
- New Zealand7 open trials
- Poland6 open trials
- Canada6 open trials
- Brazil6 open trials
- Türkiye6 open trials
- South Korea6 open trials
- Denmark5 open trials
- Norway5 open trials
- Israel5 open trials
- Malaysia4 open trials
- Taiwan4 open trials
- Greece4 open trials
- Austria4 open trials
- Pakistan3 open trials
- India3 open trials
- Czechia3 open trials
- Hungary3 open trials
- Argentina3 open trials
- Sweden2 open trials
- Singapore2 open trials
- Belgium2 open trials
- Russia2 open trials
- Switzerland2 open trials
- Slovenia2 open trials
- Japan2 open trials
- Hong Kong2 open trials
- Thailand2 open trials
- Colombia1 open trial
- Mexico1 open trial
- Chile1 open trial
- Finland1 open trial
- Slovakia1 open trial
- Jordan1 open trial
- Lebanon1 open trial
- Portugal1 open trial
- United Arab Emirates1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Amsterdam UMC Location University of Amsterdam
Amsterdam, Netherlands
2 trials · 30 publications · ROR
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, Italy
5 trials · 7 publications · ROR
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
3 trials · 9 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
New in the registry
Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3
NCT07919353 · No phase · United States
Source: ClinicalTrials.govClosed for recruitment
NCT07037771 · Phase 3 · Austria, Australia, Belgium, Brazil, Canada, Czechia
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
NCT07102511 · Phase 3 · Israel, Norway, New Zealand, United States, South Africa
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
Semaglutide Treatment in Type 1 Diabetes
NCT06909006 · Phase 3 · Denmark
Source: ClinicalTrials.govOpened for recruitment
NCT07037771 · Phase 3 · Austria, Australia, Belgium, Brazil, Canada, Czechia
Source: ClinicalTrials.govOpened for recruitment
Semaglutide Treatment in Type 1 Diabetes
NCT06909006 · Phase 3 · Denmark
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded 14 Oct 2026
Completed100000 participants
NCT07892092
Long-Term Cardiovascular Impact of ArmoLIPID Cholesterol Plus: An In Silico Study Using Digital Twins
No phaseEnded 28 Aug 2026
Phase 4Ended 30 Jun 2026
Completed126 participants
NCT07255820
Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
No phaseEnded 30 Jun 2026
No phaseEnded 4 Jun 2026
No phaseEnded 30 May 2026
No phaseEnded 22 May 2026
Completed278 participants
NCT05988866
Effects of a Digital Health Application (Lipodia) on LDL-cholesterol Levels
Phase 3Ended 12 May 2026
Completed158 participants
NCT06717360
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R
No phaseEnded 1 May 2026
Completed898 participants
NCT06423365
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
No phaseEnded 27 Apr 2026
No phaseEnded 3 Apr 2026
Completed160 participants
NCT07026266
Study on the Effect of the Intake of a Calcium-bicarbonate Water on Cholesterol Levels
No phaseEnded 1 Apr 2026
Withdrawn before start0 participants
NCT05798390
Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia
Reason given: Due to patient availability
No phaseEnded Mar 2026
Withdrawn before start0 participants
NCT05720156
Immunomodulatory Effects of PCSK9 Inhibition
Reason given: Lack of Feasibility
No phaseEnded 31 Mar 2026
Phase 2Ended 12 Feb 2026
Completed156 participants
NCT07421232
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Phase 4Ended 13 Jan 2026
Phase 4Ended 2 Jan 2026
No phaseEnded 31 Dec 2025
Phase 4Ended Dec 2025
Withdrawn before start0 participants
NCT06789432
Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population
Reason given: Withdrawn by the sponsor before any participant was enrolled. Protocol-specified screening and randomization were not initiated at the study site. Not related to participant safety.
No phaseEnded 22 Dec 2025
Completed11991 participants
NCT07409636
A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients
Show more
No phaseEnded 28 Nov 2025
Phase 3Ended 18 Nov 2025
Phase 2Ended 13 Nov 2025
Stopped early18 participants
NCT05217667
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
Reason given: Business decision, unrelated to safety concerns.
- Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. · The lancet. Diabetes & endocrinology, 2026
Phase 3Ended 11 Nov 2025
Completed151 participants
NCT06165250
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
Phase 1Ended 29 Oct 2025
Phase 3Ended 21 Oct 2025
Completed184 participants
NCT07444762
Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A
Phase 4Ended 15 Oct 2025
Completed180 participants
NCT06925100
A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan
- Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients With Hypercholesterolemia: A Pragmatic Phase 4 Study (CLEAR Taiwan Study). · Journal of the American Heart Association, 2026
No phaseEnded 15 Oct 2025
No phaseEnded 30 Sept 2025
Completed60 participants
NCT06822621
Functional Cereal Products and Contribution to the Regulation of Metabolism and Obesity-induced Chronic Low-grade Inflammation.
No phaseEnded 29 Aug 2025
Completed140 participants
NCT05218005
Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia
Phase 3Ended 21 Aug 2025
Completed257 participants
NCT05238519
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
Phase 3Ended 19 Aug 2025
No phaseEnded 30 Jul 2025
Completed1839 participants
NCT05559606
An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe
Phase 3Ended 28 Jul 2025
Completed2912 participants
NCT05952856
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
No phaseEnded 22 Jul 2025
Completed116 participants
NCT05758779
The Danish Familial Hypercholesterolemia Organized Coronary Screening Trial
Phase 3Ended 30 Jun 2025
No phaseEnded 13 Jun 2025
Completed1538 participants
NCT07382778
Efficacy and Safety of Livalozet® in Hypercholesterolemic Patients With and Without Diabetes
Phase 2Ended 4 Jun 2025
Phase 3Ended 30 May 2025
Completed129 participants
NCT06747936
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
Phase 4Ended 14 May 2025
Completed81 participants
NCT04608474
Lipid Management in Renal Transplant Recipients Using Evolocumab.
No phaseEnded 13 May 2025
Phase 3Ended 8 May 2025
Completed618 participants
NCT07295418
A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia
Phase 3Ended 7 Apr 2025
Phase 3Ended 28 Mar 2025
Completed301 participants
NCT06450366
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
- Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. · Journal of the American College of Cardiology, 2026
No phaseEnded 27 Mar 2025
No phaseEnded 21 Mar 2025
Phase 4Ended 19 Mar 2025
Phase 4Ended 19 Mar 2025
Phase 3Ended 18 Mar 2025
Completed10 participants
NCT05611528
Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia
Phase 1Ended 14 Feb 2025
Completed13 participants
NCT05398029
A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease
No phaseEnded 31 Dec 2024
No phaseEnded 29 Nov 2024
Completed26 participants
NCT05901246
Anti-eryptotic Effect of a Food Supplement with Plants Sterols in Hypercholesterolemia Treated with Statins
Phase 3Ended 27 Nov 2024
Completed141 participants
NCT04652726
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
- Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial. · The lancet. Diabetes & endocrinology, 2026
Phase 3Ended 18 Nov 2024
Completed13 participants
NCT04659863
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
No phaseEnded 15 Nov 2024
Completed62 participants
NCT06350604
Project WHADE: A Partner-Based Physical Activity Program for Women
Early Phase 1Ended 31 Oct 2024
Phase 3Ended 24 Oct 2024
Phase 3Ended 16 Oct 2024
Completed407 participants
NCT06005597
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Phase 3Ended 15 Oct 2024
Completed166 participants
NCT05004675
Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients
Phase 3Ended 26 Sept 2024
Completed2530 participants
NCT05142722
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
Not medical advice. fetched 8 Nov 2026